YTEN - Yield10 Bioscience, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.80
+0.52 (+8.28%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close6.28
Open6.90
Bid6.55 x 800
Ask6.80 x 800
Day's Range6.36 - 7.70
52 Week Range4.40 - 70.80
Volume292,248
Avg. Volume134,814
Market Cap230.577M
Beta (5Y Monthly)3.03
PE Ratio (TTM)N/A
EPS (TTM)-0.70
Earnings DateAug 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.50
  • Have Insiders Been Buying Yield10 Bioscience, Inc. (NASDAQ:YTEN) Shares?
    Simply Wall St.

    Have Insiders Been Buying Yield10 Bioscience, Inc. (NASDAQ:YTEN) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...

  • GlobeNewswire

    Yield10 Bioscience Submits "Am I Regulated?" Letter to USDA-APHIS BRS for CRISPR Genome-Edited C3007 in Camelina to Pave the Way for U.S. Field Tests

    Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that it has submitted an "Am I Regulated?" letter to USDA-APHIS's Biotechnology Regulatory Services (BRS) to confirm that the use of CRISPR genome-edited trait C3007 in Camelina sativa plant lines for increased oil content does not meet the definition of a regulated article under 7 CFR Part 340 regulations. Once regulatory status of the plants is confirmed, Yield10 plans to conduct field tests of CRISPR genome-edited Camelina plants in the United States. “We have applied considerable effort and resources into the discovery and early development of a portfolio of novel traits with the potential to increase oil content in oilseed crops,” said Dr. Kristi Snell, Ph.D., Chief Science Officer of Yield10 Bioscience.

  • GlobeNewswire

    Yield10 Bioscience Announces 1-for-40 Reverse Stock Split

    Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that it will effect a 1-for-40 reverse stock split of its common stock, following stockholder approval of the reverse stock split at the Company's special stockholders meeting held on January 9, 2020. The 1-for-40 reverse stock split will be effective as of the close of business on Wednesday, January 15, 2020 and the Company's common stock will begin trading on a split-adjusted basis on Thursday, January 16, 2020. The reverse stock split will reduce the number of shares of the Company’s common stock currently outstanding from 39,986,201 shares to 999,655 shares.

  • Yield10 shareholders approve reverse stock split
    American City Business Journals

    Yield10 shareholders approve reverse stock split

    Woburn-based agricultural company Yield10 Bioscience Inc. received shareholder approval to undergo a reverse stock split in order to avoid being delisted by the Nasdaq, the company revealed in a public filing Thursday.

  • Agri-biotech Yield10 plans reverse stock split to avoid Nasdaq delisting
    American City Business Journals

    Agri-biotech Yield10 plans reverse stock split to avoid Nasdaq delisting

    Woburn-based agricultural company Yield10 Bioscience Inc. is seeking stakeholders approval to effect a reverse stock split to address the risk of being delisted by the Nasdaq, the company revealed in a recent public filing.

  • Hedge Funds Watching Yield10 Bioscience, Inc. (YTEN) From Afar
    Insider Monkey

    Hedge Funds Watching Yield10 Bioscience, Inc. (YTEN) From Afar

    Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]

  • GlobeNewswire

    Yield10 Bioscience Announces Closing of $11.5 Million Equity Offering and Full Exercise of Over-allotment Option

    Yield10 Bioscience, Inc. (YTEN) an agricultural bioscience company which uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, announced today the closing of an equity offering, which consisted of an underwritten public offering of units and a private placement of units for gross proceeds of $11.5 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Yield10 Bioscience. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS), is sole book-running manager and placement agent in connection with the public offering and the private placement.

  • GlobeNewswire

    Yield10 Bioscience Announces Pricing of $10.75 Million Equity Offering

    Yield10 Bioscience, Inc. (YTEN) an agricultural bioscience company which uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, announced today the pricing of a $10,750,000 equity offering, which consisted of an underwritten public offering of units and a private placement of units for gross proceeds of $10.75 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Yield10 Bioscience. In a concurrent private placement, investors affiliated with Jack W. Schuler have agreed to purchase 5,750 unregistered units, priced at $1,000 per unit, with each unit consisting of one share of Series B preferred stock, having a conversion price of $0.20, seven and one-half year warrants to purchase 5,000 shares of common stock with an exercise price of $0.20 per share, and two and one-half year warrants to purchase 5,000 shares of common stock with an exercise price of $0.20 per share.

  • GlobeNewswire

    Yield10 Bioscience Announces Third Quarter 2019 Financial Results

    WOBURN, Mass., Nov. 12, 2019 -- Yield10 Bioscience, Inc. (NASDAQ:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for.

  • GlobeNewswire

    Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Present at the 7th Plant Genomics & Gene Editing Congress

    Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that Kristi Snell, Ph.D., Yield10’s Chief Science Officer, will present today at the 7th Plant Genomics & Gene Editing Congress. At the 7th Plant Genomics & Gene Editing Congress, Dr. Snell will present a talk titled “Crop Trait Development: Target selection and validation using the GRAIN Platform.” In the presentation, Dr. Snell will discuss strategies the Yield10 team has employed to identify and edit novel gene targets using CRISPR genome editing to improve seed yield and oil content in oilseed crops.

  • GlobeNewswire

    Yield10 Bioscience Signs Research Agreement with J. R. Simplot to Evaluate New Traits to Produce High Yielding, Sustainable Potato Crop

    Yield10 Bioscience, Inc. (YTEN) today announced that it has signed a research agreement with Boise, Idaho-based J. R. Simplot Company, to evaluate three novel yield traits in potato. Under the agreement with Yield10, Simplot plans to conduct research with these yield traits within its research and development program as a strategy to improve crop performance and sustainability. The novel crop yield traits included in the research agreement are C3003, C3004 and C4001.

  • Should You Worry About Yield10 Bioscience, Inc.'s (NASDAQ:YTEN) CEO Salary Level?
    Simply Wall St.

    Should You Worry About Yield10 Bioscience, Inc.'s (NASDAQ:YTEN) CEO Salary Level?

    Olly Peoples became the CEO of Yield10 Bioscience, Inc. (NASDAQ:YTEN) in 2016. This analysis aims first to contrast...

  • GlobeNewswire

    Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Highlight Camelina Platform for Producing PHB Biomaterials to Improve Water Quality at International Scientific Conference

    Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that Kristi Snell, Ph.D., Yield10’s Chief Science Officer, will present at the 3rd International Conference on Plant Synthetic Biology, Bioengineering and Biotechnology which is being held October 4-6 in Cambridge, UK. Dr. Snell’s presentation, entitled “Breakthroughs in Plant Based PHB Production: Harnessing Nature to Heal Nature,” will be part of Session 5: Novel Bioproducts which is scheduled from 12:30 pm to 2:15 pm local time on Saturday, October 5. Dr. Snell will discuss the progress made by the Yield10 team to achieve plant-based production of the simplest member of the natural PHA biopolymer family, PHB (polyhydroxybutyrate).

  • Do Insiders Own Shares In Yield10 Bioscience, Inc. (NASDAQ:YTEN)?
    Simply Wall St.

    Do Insiders Own Shares In Yield10 Bioscience, Inc. (NASDAQ:YTEN)?

    A look at the shareholders of Yield10 Bioscience, Inc. (NASDAQ:YTEN) can tell us which group is most powerful...

  • GlobeNewswire

    Yield10 Bioscience Expands Research License with Bayer for Evaluation of a Novel C3004 Yield Trait Gene in Soybean

    Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that it has expanded its non-exclusive research license with Bayer for soybean crop research to include a new discovery related to its C3004 yield trait gene. Yield10 is developing C3003 and C3004 as novel yield trait genes to increase seed yield in commercially important crops.  Under the amended research license, Bayer will have access to these new developments from Yield10’s C3004 program and new advanced technology related to the C3004 trait and its potential to increase seed yield.

  • GlobeNewswire

    Yield10 Bioscience Announces Second Quarter 2019 Financial Results

    WOBURN, Mass., Aug. 12, 2019 -- Yield10 Bioscience, Inc. (NASDAQ:YTEN), an agricultural bioscience company which uses its “Trait Factory” to develop high value seed traits for.

  • ACCESSWIRE

    Yield10 Bioscience, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 12, 2019 / Yield10 Bioscience, Inc. (NASDAQ: YTEN ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 12, 2019 at 4:30 ...

  • GlobeNewswire

    Yield10 Bioscience Announces Notice of Allowance for U.S. Patent Covering Crop Yield Trait C4001

    The Notice of Allowance relates to Yield10’s U.S. patent application US15/897,958 titled “Transcriptional Regulation for Improved Plant Productivity.” This patent application describes the C4001 yield trait, which is based on the discovery of novel transcription factor genes in plants where an increase in the productivity of photosynthesis results in significant increases in biomass yield and stress tolerance.

  • GlobeNewswire

    Yield10 Bioscience to Announce Second Quarter 2019 Financial Results and Host a Conference Call on Monday, August 12, 2019

    WOBURN, Mass., Aug. 06, 2019 -- Yield10 Bioscience, Inc. (NASDAQ: YTEN), an agricultural bioscience company which uses its “Trait Factory” to develop high value seed traits for.

  • GlobeNewswire

    Yield10 Bioscience Granted U.S. Patent Covering Crop Yield Trait C3003

    The U.S. patent 10,337,024 is entitled, “Plants with enhanced photosynthesis and methods of manufacture thereof.” Yield10 is the exclusive licensee of this intellectual property from The University of Massachusetts. C3003 is believed to play a role in carbon capture and directing carbon to seed. Under research licenses with Yield10, two major seed companies are progressing evaluation of C3003 in soybean and forage sorghum, respectively.

  • GlobeNewswire

    Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Present at the Plant Biology 2019 Conference

    Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that Kristi Snell, Ph.D., Yield10’s chief science officer, will present at the Plant Biology 2019 conference, the annual meeting of the American Society of Plant Biologists (ASPB).  The conference is being held August 3-7 in San Jose, California. At the Plant Biology 2019 Conference, Dr. Snell will serve as Chair for “Concurrent Symposium 20: Edited for Content” session, which is scheduled from 3:15 pm to 5:00 pm local time on Monday, August 5. Dr. Snell will moderate this session and present a talk titled “Genome editing to increase seed yield and oil content.” In the presentation, Dr. Snell will discuss strategies the Yield10 team has employed to identify and edit novel gene targets using CRISPR genome editing to improve seed yield and oil content in oilseed crops.

  • How Many Yield10 Bioscience, Inc. (NASDAQ:YTEN) Shares Did Insiders Buy, In The Last Year?
    Simply Wall St.

    How Many Yield10 Bioscience, Inc. (NASDAQ:YTEN) Shares Did Insiders Buy, In The Last Year?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

  • GlobeNewswire

    Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Highlight Unique Aspects of the Company’s GRAIN Technology Platform to Identify Novel Traits for Crops at the 3rd Precision CRISPR & NBT AgBio Congress

    Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company which uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that Kristi Snell, Ph.D., Yield10’s chief science officer, will present at the 3rd Precision CRISPR & NBT AgBio Congress which is being held June 24-26 in San Diego, California. Dr. Snell will present a talk entitled “Exploring Novel Approaches for Gene Selection and Trait Validation in Crops.” The presentation will be part of the “Novel Approaches Beyond Genomics to Improve Yield, Productivity and Resistance” session which is scheduled from 11:10 am to 12:40 pm local time on June 26. In her presentation, Dr. Snell will discuss the components of Yield10’s proprietary GRAIN (Gene Ranking Artificial Intelligence Network) platform, highlighting recent advancements.

  • GlobeNewswire

    Yield10 Bioscience Files U.S. Patent Application Covering New Technology Enabling Low-cost Production of PHA-based Biomaterials in Camelina

    Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that the Company has filed a U.S. Patent application for new technology enabling low-cost production of PHA-based (“polyhydroxyalkanoate”) biomaterials in Camelina sativa, an oilseed crop. PHA-based biomaterials are of significant interest for their use in water treatment to remove nitrogen and phosphates, and as a biodegradable replacement for petroleum plastics in a range of applications. The new Yield10 patent application describes a discovery around maintaining the viability and vigor of Camelina seed containing high levels of PHA biopolymer.